Work

1406P Interim results of a phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)

Year: 2022

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2022.07.1892

Authors: J. Lang, S.T. Tagawa, S. Slovin, H. Emamekhoo, D. Rathkopf, W. Abida, K. Autio, H. Xiao, A.M. Molina, J. Eickhoff, J.M. Sperger, S. Dehm, D.M. Nanus, C.E. Kyriakopoulos

Institutions: University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, NewYork–Presbyterian Hospital, Weill Cornell Medical Center, Memorial Sloan Kettering Cancer Center, University of Minnesota, Masonic Cancer Center, Weill Cornell Medicine

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4295837515

FWCI: 0.971

Cites:

Cited by: 9

Related to: 10